Sage Journals: Discover world-class research

Abstract

An accurate and early diagnosis of Alzheimer’s disease (AD) is important to select optimal patient care and is critical in current clinical trials targeting core AD neuropathological features. The past decades, much progress has been made in the development and validation of cerebrospinal fluid (CSF) biomarkers for the biochemical diagnosis of AD, including standardization and harmonization of (pre-) analytical procedures. This has resulted in three core CSF biomarkers for AD diagnostics, namely the 42 amino acid long amyloid-beta peptide (Aβ_1-42), total tau protein (T-tau), and tau phosphorylated at threonine 181 (P-tau₁₈₁). These biomarkers have been incorporated into research diagnostic criteria for AD and have an added value in the (differential) diagnosis of AD and related disorders, including mixed pathologies, atypical presentations, and in case of ambiguous clinical dementia diagnoses. The implementation of the CSF Aβ_1-42/Aβ_1-40 ratio in the core biomarker panel will improve the biomarker analytical variability, and will also improve early and differential AD diagnosis through a more accurate reflection of pathology. Numerous biomarkers are being investigated for their added value to the core AD biomarkers, aiming at the AD core pathological features like the amyloid mismetabolism, tau pathology, or synaptic or neuronal degeneration. Others aim at non-AD neurodegenerative, vascular or inflammatory hallmarks. Biomarkers are essential for an accurate identification of preclinical AD in the context of clinical trials with potentially disease-modifying drugs. Therefore, a biomarker-based early diagnosis of AD offers great opportunities for preventive treatment development in the near future.

Keywords

Alzheimer’s disease amyloid biomarkers cerebrospinal fluid dementia diagnosis mild cognitive impairment neuropathology tau

INTRODUCTION

An accurate and early diagnosis of Alzheimer’s disease (AD) is important to select the optimal patient care and is critical in current clinical trials targeting core AD neuropathological features. Its value will grow even more so when a disease modifying treatment is available. To date, diagnosis of AD is still based on a full clinical work-up, including neuropsychological testing [1] and brain imaging such as magnetic resonance imaging (MRI). However, clinical dementia diagnosis does not always correspond to the neuropathological definite diagnosis with clinical diagnostic accuracy levels ranging between 82% and 84% [2, 3]. When a clinician should discriminate AD from a non-AD dementia relying on (non-biomarker based) clinical diagnostic criteria, 16% are misdiagnosed and 16% of the patients have a doubtful AD versus non-AD diagnosis [2 , 5]. Therefore, it is important to increase the clinical diagnostic accuracy, which will even be harder at an early stage of the disease. Since biochemical changes are believed to take place and be detectable through biomarkers around two decades before clinical symptom onset [6], they will be important tools in the clinical setup for early and differential diagnosis of AD.

Several attempts have been made to counteract the effects of amyloid-β (Aβ) mismetabolism, which is assumed to be one of the key pathogenic events in AD. However, all but one clinical trials have failed to reverse or slow down cognitive decline [7]. Possible reasons for the failures may be that non-homogeneous groups of patients have been included in the trials, the treatment has been administered too late in the course of the disease or has been too short, and/or that the Aβ aggregation is not the key event in AD.

Also driven by the need of clinical trials to select ‘pure’ AD subjects early in the course of the disease, much effort has been put in developing biomarkers for AD during the past two decades (see Alzforum biomarker database and meta-analyses at http://www.alzforum.org/alzbiomarker) [8]. This has resulted in three core cerebrospinal fluid (CSF) biomarkers for AD diagnostics, namely the 42 amino acid long amyloid-beta peptide (Aβ_1-42), total tau protein (T-tau), and tau phosphorylated at threonine 181 (P-tau₁₈₁) [9]. A biomarker classification scheme, which is based on the early findings and interpretations of the above CSF biomarkers by Blennow et al. [10], has been suggested as a tool to assess the pathophysiology in the brain independent of the clinical evaluation. This so called “A/T/N” system, captures the three main neuropathological findings related to AD. The A refers to the Aβ pathology measured by either amyloid PET or CSF Aβ_1-42, T represents tangle pathology and is assessed by either tau PET or CSF P-tau, and N stands for neurodegeneration or neuronal injury detected by either [18F]-fluorodeoxyglucose-PET, structural MRI, or CSF T-tau [11].

Biomarkers have been incorporated into research diagnostic criteria for AD [12 –14] and, although the clinical examination (including full neuropsychological evaluation) is still the basis for AD diagnosis [1], these biomarkers are being introduced in daily clinical practice as in vivo surrogate markers for the confirmation of AD neuropathology. The core CSF AD biomarkers increase the diagnostic accuracy for diagnosing AD (mainly in cases with atypical presentations), also in its prodromal phase (mild cognitive impairment (MCI) due to AD) [15, 16] and are able to differentiate between AD and psychiatric disorders [17]. The CSF biomarkers are useful to diagnose AD in patients with ambiguous clinical dementia diagnoses [4] and in cases with mixed brain pathology like AD with cerebrovascular disease [5 , 19].

During ten years of CSF AD biomarker analyses, the number of samples referred to the BIODEM lab at UAntwerp from clinical centers has increased with 238% [20]. Due to the revisions of diagnostic criteria for AD diagnosis and the herein described use of CSF biomarkers [12 –14], confidence in the importance of biomarkers has grown. Not only are they used more often by clinicians, they are also useful in clinical trials as enrichment strategy or outcome measures due to their in vivo pathophysiological characteristics [21]. However, there is a general shift from samples referred for neurochemical confirmation of AD diagnosis to referrals for differential AD versus non-AD dementia diagnosis. This may be due to the growing scientific support for biomarker-based differential diagnosis between AD and non-AD dementias [22], also in the prodromal phase [23].

BIOMARKER ASSOCIATION WITH NEUROPATHOLOGY AND DETECTION OF DEFINITE AND CLINICAL AD

A biomarker should be readily accessible, accurately indicating a biological or pathological state and preferably inexpensive. In case of neurodegenerative biomarkers, the choice of CSF over blood biomarkers, at least in the case of Aβ_1–42, is mainly based on the fact that the central nervous system is secluded from the systemic circulation, which precludes direct translation of biomarker findings of the brain to the periphery. This has been supported by studies in plasma showing conflicting results, and in the case of Aβ_1–42 for instance no overall difference between AD and controls were found in a meta-analysis [8] (http://www.alzforum.org/alzbiomarker). Furthermore, no correlation between plasma and CSF levels of the Aβ_1–42 biomarker has been found [24, 25]. Tau on the other hand have shown more potential as a plasma or serum biomarker for the differentiation between AD and controls [8] (http://www.alzforum.org/alzbiomarker); however, speaking against a direct translation of CSF values into plasma is the finding that nor tau CSF levels correlate with its plasma counterpart [26]. Nevertheless in CSF, Aβ_1–42, T-tau, and P-tau₁₈₁ have shown to be consistently altered in AD versus controls, also in the prodromal phase [8] (http://www.alzforum.org/alzbiomarker).

The BIODEM lab was the first to demonstrate the diagnostic value of the CSF biomarkers Aβ_1-42, T-tau, and P-tau₁₈₁ in clinical AD using the neuropathological diagnosis as a reference [2, 27]. The study demonstrated that all three biomarkers provide useful information, showing promising sensitivity and specificity values that systematically exceed the 80% threshold. The use of a biomarker-based model in patients with a clinically ambiguous diagnosis, resulted in a correct diagnosis in the majority of autopsy-confirmed AD and non-AD cases, indicating that biomarkers have an added diagnostic value in these cases [1 , 4].

Moreover, Aβ_1–42 has proven its potential to mirror the build-up of plaques, which is supported by the inverse correlation between the CSF Aβ_1–42 levels and the amount of amyloid plaques found at neuropathological examination of AD brains [28] as well as the in vivo association with cortical amyloid load as measured by amyloid PET in patients with AD [29 –31]. The present core AD CSF biomarkers, including Aβ_1–42, T-tau, and P-tau₁₈₁, have recently been incorporated into the research diagnostic criteria of AD, with a CSF profile suggestive for AD being low Aβ_1–42 in combination with high T-tau and/or P-tau₁₈₁ levels [14].

THE ADDED VALUE OF CSF BIOMARKERS FOR EARLY AND DIFFERENTIAL AD DIAGNOSIS

It should be emphasized that biomarkers are especially important for the selection of preclinical AD subjects (who are asymptomatic at risk for AD or subjects who suffer from subjective cognitive decline [SCD] due to AD) and for the selection of patients in the earliest symptomatic stages of AD (prodromal AD or MCI due to AD). SCD and MCI are both very heterogeneous syndromes and when assessed in a large clinical cohort less than 25% of the subjects converted to dementia after an extensive follow-up period of 6 years. The majority of these SCD and MCI subjects (42%) developed dementia due to AD, while subjects with mixed AD with cerebrovascular disease and pure vascular dementia (VaD) were the second most common diagnoses representing about a quarter each of the converters [32]. In this particular setting, CSF Aβ_1–42 would portrait as a very attractive biomarker for early AD detection since both CSF T-tau and P-tau₁₈₁ alterations seem to occur at a later time point in the disease process closer to clinically detectable dementia [33]. However, it has previously been suggested and shown that a combination of the core AD biomarkers is superior compared with the single biomarkers alone, especially for differential diagnosis [2]. Investigating autopsy-confirmed AD and non-AD dementia patients has also improved our knowledge and insights with regard to the differential diagnostic value of the existing AD CSF biomarkers. An added discriminatory value for AD versus non-AD dementia was shown for P-tau₁₈₁ to the panel of Aβ_1-42 and T-tau [34, 35] and, furthermore, that the ratio of Aβ_1-42/P-tau₁₈₁ has shown a higher diagnostic accuracy than Aβ_1-42, T-tau, and P-tau₁₈₁ alone, but also than the Aβ_1-42/T-tau ratio to discriminate between AD and non-AD dementias. This clearly shows the importance of P-tau₁₈₁ in the biomarker panel for differential dementia diagnosis [2 , 35].

Although there is strong evidence for the importance of CSF Aβ_1–42 as a biomarker for early AD detection, there are still limitations to be overcome. One such limitation is the overlap of CSF Aβ_1–42 between different neurodegenerative disorders. For instance, decreased CSF levels of Aβ_1–42 have also been observed in patients with prodromal and manifest (subcortical) VaD [34 , 37], dementia with Lewy bodies (DLB) [34, 38], Creutzfeldt–Jakob disease (CJD) [34, 39], and frontotemporal lobar degeneration (FTLD) [34, 40] compared with healthy individuals. Though the Aβ_1–42 levels are most often still lower in AD compared with VaD and DLB, a significant overlap nevertheless limits the discrimination. Concomitant AD pathology in DLB has been shown to occur in 72% of autopsy-confirmed DLB patients, which was reflected by low CSF Aβ_1-42 values [38]. While AD pathology is often found in combination with both DLB and cerebrovascular disease [2, 38], decreased Aβ_1–42 levels in CSF of patients with pure VaD (related to subcortical small vessel disease), CJD or FTLD may on the other hand be related to other pathophysiological characteristics than plaque burden.

The introduction of Aβ peptide ratios was proposed already in the late 1990s to improve the AD differential diagnosis [41, 42]. It has previously been shown that CSF Aβ_1–42 and florbetapir-PET showed a nonlinear association with pathological values of CSF Aβ_1–42 preceding PET abnormalities [29] and it has been suggested that CSF Aβ_1–42 is an earlier marker of brain amyloid pathology compared with PET [43]. However, this has more or less been disputed by the finding that the CSF Aβ_1–42/Aβ_1–40 ratio shows a higher concordance with amyloid load in the brain as assessed by PET compared with Aβ_1–42 alone [31 , 45]. The Aβ_1–42/Aβ_1–40 ratio is decreased in AD and more accurately differentiates between AD and controls, FTLD, VaD, and DLB, due to the latter four groups having ratios that approach control levels because of decreased concentrations in both Aβ_1–42 and Aβ_1–40. This finding supports the increased association of the CSF Aβ_1–42/Aβ_1–40 ratio to pathology as the above non-AD dementias are not affected by plaque pathology in their purest forms [44]. Furthermore, the ratio shows a high concordance with PET, also in subjects with subjective cognitive decline and mild cognitive impairment (AUC≥0.93), indicating a high agreement at the early stages of disease [46]. However, more comparative studies are needed to investigate the biomarker characteristics for early pre-clinical detection of amyloid pathology with regard to the timing of CSF Aβ_1–42/Aβ_1–40 ratio and amyloid PET. The Aβ_1–42/Aβ_1–40 ratio has also been shown to perform equally well as the combination of Aβ_1–42, P-tau₁₈₁, and T-tau in differentiating between AD and other non-AD dementias [47]. In another study, it was shown that adding the Aβ ratio to the core biomarkers improved the accuracy when distinguishing between definite AD and non-AD dementias in cases with intermediate P-tau₁₈₁ [48], indicating its potential usefulness as a biomarker for differential dementia diagnosis. Along the same line, the added value to the core biomarkers has also been assessed in a clinical setting where it was shown that in cases with a discrepancy in the AD core biomarker profile, the Aβ_1–42/Aβ_1–40 ratio was in agreement with the clinical diagnosis in over 50% of the cases [49]. All together, these findings speak in favor of the added value of the Aβ_1–42/Aβ_1–40 ratio for differential diagnosis, when alterations in CSF tau are yet to be seen. Other ratios that have been less well investigated but still show potential as biomarkers are Aβ_1–42/Aβ_1–38 and Aβ_1–42/Aβ_1–37 [35]. In this study, it was concluded that Aβ_1–42/Aβ_1–38 ratio performed the best for the separation between AD and DLB, and that it outperformed the single AD biomarkers. Also, Aβ_1–42/Aβ_1–37 was shown to have an added value for the differentiation between AD and FTLD [35]. More studies are needed in order to determine which Aβ peptide ratios achieve the best separation in different diagnostic settings.

The CSF Aβ_1–42/Aβ_1–40 ratio has been shown to be superior to Aβ_1–42 alone when concerned with the distinction between MCI patients who progress to AD dementia and MCI patients who remain stable [50]. The early diagnostic value of the existing biomarker panel might be improved by the addition of Aβ_1-40, since formation of amyloid-plaques is believed to be initiated up to twenty years before the onset of the clinical symptoms. The use of low CSF Aβ_1-42 and the CSF Aβ_1-42/Aβ_1-40 ratio opens new possibilities for the accurate identification of ‘asymptomatic at risk for AD’ subjects for clinical trials.

NEW AD AND NON-AD RELATED BIOMARKERS FOR IMPROVED DIFFERENTIAL DIAGNOSIS

Numerous biomarkers have been investigated for their added value to the core AD biomarkers in early detection or differential diagnosis of AD. Several of those have aimed at the AD core pathological features like the amyloid mismetabolism, tau pathology, or synaptic or neuronal degeneration. Others have aimed at non-AD neurodegenerative, vascular, or inflammatory hallmarks.

More or less overlapping results have been found for the differentiation of AD and non-AD dementias including DLB, FTLD, and VaD using the core AD biomarkers Aβ_1-42, T-tau, and P-tau₁₈₁. When concerned with FTLD-tau, tau CSF levels are usually intermediate ranging from normal to abnormal, precluding its usability as a biomarker for differential diagnosis [51]. Other tau species, with for instance different modifications, may be more specific for either AD or FTLD-tau pathology increasing its clinical utility. Based on this thought, an assay measuring non-phosphorylated tau at positions T175 and T181 was developed, which was highly accurate at detecting MCI due to AD when compared to healthy controls [52]. However, there was no added value compared with the core AD biomarkers for the differential diagnosis of AD with regard to non-AD neurodegenerative diseases, including FTLD and DLB. Neither was there any added value for the differentiation of AD or FTLD from healthy controls [40].

Other core AD biomarker than Aβ_1-42 representing Aβ or amyloid-β protein precursor (AβPP) metabolism have also been investigated for their ability to discriminate AD from healthy controls, such as Aβ_1-40 and Aβ_1-38 peptides as well as soluble AβPPα and β protein fragments. They have shown to be unaltered in AD [8 , 54], but decreased levels have been associated with inflammation, cerebrovascular disease, and white matter lesions [54, 55]. As mentioned before, the CSF Aβ_1-42/Aβ_1-40 ratio is likely to perform with a higher specificity than for instance Aβ_1-42/P-tau₁₈₁ to discriminate between AD and VaD [56] as well as FTLD and DLB [35]. These findings are of outermost importance for the accuracy of detection of amyloid plaque pathology that characterizes AD, both for clinical practice as well as for patient inclusion into clinical trials. Furthermore, these biomarkers may contribute to detect cerebrovascular disease that may also affect the trajectory of AD under the influence of mixed pathology.

As synaptic and neuronal degeneration is assumed to correlate with cognitive decline in AD, being able to monitor neurodegeneration through synaptic function would be an important advantage, both clinically and in clinical trials to detect disease progression or treatment efficacy. For this purpose, the postsynaptic protein neurogranin has been investigated and was found to be increased in CSF of patients with MCI and dementia due to AD as compared with healthy controls [26, 57], while in paired plasma samples no difference was found [26]. As CSF neurogranin and tau has been found to correlate strongly, its added value to the core biomarkers needs further attention as well as the relation to clinical parameters [26, 57].

Neurofilament light (Nf-L) is another marker of neuronal integrity reflecting axonal damage of the subcortical white matter. Nf-L is therefore considered as a candidate biomarker for subcortical small vessel disease and related dementia [58 –60] as it has been found to be associated with white matter hyperintensities [55, 61]. Nf-L has been found to be elevated in CSF from patients with subcortical VaD and mixed AD with subcortical small vessel disease as well as in FTLD [36 , 62]. However, it has also been proposed as a biomarker for AD [8], if Nf-L in this case is related to concomitant cerebrovascular disease remains to be clarified. The relation to cerebrovascular disease has also been corroborated by findings of increased levels in stroke [63]. So far, Nf-L is the only marker that has been shown to be directly transferrable from CSF to plasma and show potential as a clinical tool to predict cognitive decline and brain atrophy in AD [64]. Another marker reflecting axonal damage or remodeling of the myelin sheet is myelin basic protein (MBP), which has also been found to be increased in subcortical VaD and stroke [37, 63] and associated with white matter lesions [55]. If MBP more specifically reflects white matter lesions related to subcortical VaD than Nf-L remains to be shown.

Other markers that have been proposed to improve the differential diagnosis between AD and (subcortical) VaD are biomarkers reflecting blood-brain barrier (BBB) dysfunction, such as albumin ratio, and markers related to inflammation and opening of the BBB [58, 59]. The albumin ratio has consistently been found to be increased in subcortical VaD compared with AD and healthy controls [36, 37, 62]. Moreover, matrix metalloproteinases (MMP-9) known to be associated with BBB opening has been found to be increased in subcortical VaD together with its endogenous inhibitor, the tissue inhibitor of metalloproteinases 1 (TIMP-1) compared with AD and healthy controls [37]. TIMP-1 has also been shown to correlate with white matter lesion volume and albumin ratio, while MMP-9 has been shown to be associated with white matter lesion progression [37, 55]. These markers and other markers related to inflammation and cerebrovascular disease needs further attention for their role to reflect subcortical small vessel disease [60].

Major molecular pathologies underlying FTLD include aggregation of transactive response DNA-binding protein of 43 kDa (TDP-43, FTLD-TDP), and tau (FTLD-tau) [65]. Having the potential to be a specific biomarker for FTLD-TDP, a lot of research was done on TDP-43. Because of low absolute levels, quantitative analysis of TDP-43 in biofluids will require a very sensitive immunoassay, preferably specific for pathological TDP-43 [66]. So far, research has not been translated into a sensitive and specific biomarker for TDP-43. The only FTLD-specific biomarker is progranulin, showing decreased concentrations in serum or plasma of subjects with GRN mutation-related FTLD (a subgroup of FTLD-TDP) [67, 68]. The diagnostic value of CSF progranulin levels is a matter of debate.

The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, which is the neuropathological hallmark of Parkinson’s disease (PD) and DLB, initiated research on α-syn as a potential CSF biomarker. α-syn is as well a constituent of glial inclusions in multiple system atrophy (MSA). Large variations in the absolute levels of α-syn in CSF and serum have bene revealed, even when the same types of α-syn isoforms were detected [69]. Differences in values are related to differences in analytical procedures, stressing the need for standardization of procedures [70]. CSF α-syn levels are decreased in PD and DLB but also in MSA [69] as compared to AD where increased levels have been reported, correlating with tau and thus possibly with neurodegeneration [71]. These data show the (differential) diagnostic potential of α-syn as a biomarker.

Fast progressive AD phenotypes often pose a diagnostic challenge and may be confused clinically with CJD. The major biological diagnostic biomarker for identifying CJD, 14-3-3 protein in CSF, unfortunately lacks specificity when confronted with a rapid dementia presentation [72, 73]. Very high T-tau concentrations may be found in AD in CSF (>1200 pg/ml), but are also indicative of CJD. In case of suspicion of CJD, analysis of the total concentration of prion protein (t-PrP) in CSF has been shown to be useful to increase the diagnostic accuracy [39]. The use of CSF t-PrP levels may be beneficial in clinical practice in addition to the current classic biomarkers.

IMPROVEMENT AND HARMONIZATION OF AD CSF BIOMARKER MEASUREMENTS

Even with an elevated confidence in the use of CSF biomarkers for the clinical work-up of dementia diagnosis, multicenter trials have shown that there is a substantial center-to-center variation [9].

Due to its favorable diagnostic characteristics and the relative inexpensive costs, much effort has been put into making Aβ_1–42 manageable as an AD biomarker worldwide to be used in daily clinical dementia practice as in vivo surrogate marker for plaque pathology [20]. Though the absolute measurements of Aβ_1–42 in CSF show inter-laboratory variability, mainly due to differences in pre-analytical and analytical procedures, which also includes the performance of different assays utilizing different calibrators. This causes an important concern as direct comparisons of measurements between laboratories and across techniques are not reliable, hampering biomarker development and their utility for clinical routine diagnosis. Storage in different tubes, different aliquot volumes, and number of freeze-thaw cycles are factors that significantly influence CSF biomarker concentrations, stressing the need for standard operating procedures for pre-analytical sample handling [74 –76]. However, it has previously been suggested [77] and verified by us that the Aβ_1-42/Aβ_1-40 ratio is a more robust measurement compared with Aβ_1-42 alone as it corrects for intra-individual confounding factors and minimizes variability due to for instance adsorption of Aβ peptides to storage tubes [76]. An exploratory study in MCI patients, on the other hand, with clinical follow-up and autopsy-confirmed AD patients provided evidence that, for a specific context of use, the impact on clinical diagnostic accuracy of biomarker concentration shifts might be lower than originally expected [78]. However, standardization of (pre)analytical sample handling as well as the cut-off thresholds should be accomplished as they influence biomarker results [74–76 , 79].

Major efforts are undertaken to overcome these problems by introducing a certified reference material and a certified reference method that can be used for value assignment of the assay calibrators [79 –81]. Also, the Alzheimer’s Association external quality control (QC) program monitors site-to-site and batch-to-batch CSF measurement variability for the purpose of enabling the participating laboratories to synchronize their procedures [82]. These efforts will lead to precise and reliable measurements between laboratories that will enable the introduction of a worldwide cut-off point for CSF Aβ_1–42, T-tau and P-tau₁₈₁ measurements for the purpose of clinical diagnostics and patient stratification in clinical trials.

With this in mind, several programs for standardization and harmonization were set up, such as the QC program of the Alzheimer’s Association, as well as the Alzheimer Biomarker Standardization Initiative (ABSI) and the JPND BIOMARKAPD consortium [79 , 82–84].

CONCLUDING REMARKS

Over the past decades, much progress has been made in the development and validation of three core CSF biomarkers for the biochemical diagnosis of AD, including standardization and harmonization of (pre-) analytical procedures. One of the most important recommendations with a significant effect on pre-analytical variability is likely to be the implementation of the Aβ_1-42/Aβ_1-40 into the clinical diagnostic work-up. This is especially important since Aβ_1-42 has proven to be the earliest marker to reflect AD related pathological changes take place in the brain and the ratio show a higher concordance with amyloid pathology. At present, low CSF Aβ_1-42 concentration is an inclusion criterion for several clinical trials with potential disease-modifying drugs that target AD in its earliest (and even preclinical) stages. Hence, biomarkers reflecting the pathology targeted by specific clinical trials are essential for inclusion but also to monitor treatment effects. Early clinical detection is also likely to become more important as soon as disease-modifying pharmacological treatment for AD is available as medications that halt or prevent the disease are likely to be most effective at an early stage, when neurodegeneration has not become too severe. The validated core AD CSF biomarkers have an added value in the early and differential diagnosis of AD and related disorders, including mixed pathologies, atypical presentations of AD, and in case of ambiguous dementia diagnosis.

Footnotes

ACKNOWLEDGMENTS

This research was funded in part by the University of Antwerp Research Fund; unrestrictive research grants from Janssen Pharmaceutica NV and ADx Neurosciences; the Flanders Impulse Program on Networks for Dementia Research (VIND); Flanders Innovation & Entrepreneurship (VLAIO). The authors acknowledge the editorial assistance of Dr. Sara Valckx.

Authors’ disclosures available online ().

References

Bier

, Verschraegen

, Vandenberghe

, Guillaume

, Picard

, Otte

, Mormont

, Gilles

, Segers

, Sieben

, Thiery

, Ventura

, De Deyn

, Deryck

, Versijpt

, Salmon

, Engelborghs

, Ivanoiu

(2015) Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer’s disease: A BeDeCo survey. Acta Neurol Belg115, 547–555.

Engelborghs

, De Vreese

, Van de Casteele

, Vanderstichele

, Van Everbroeck

, Cras

, Martin

, Vanmechelen

, De Deyn

(2008) Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. Neurobiol Aging29, 1143–1159.

Brunnstrom

, Englund

(2009) Clinicopathological concordance in dementia diagnostics. Am J Geriatr Psychiatry17, 664–670.

Le Bastard

, Martin

, Vanmechelen

, Vanderstichele

, De Deyn

, Engelborghs

(2010) Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging31, 1867–1876.

Niemantsverdriet

, Feyen

, Le Bastard

, Martin

, Goeman

, De Deyn

, Engelborghs

(2015) Overdiagnosing vascular dementia using structural brain imaging for dementia work-up. J Alzheimers Dis45, 1039–1043.

Sperling

, Aisen

, Beckett

, Bennett

, Craft

, Fagan

, Iwatsubo

, Jack

Jr , Kaye

, Montine

, Park

, Reiman

, Rowe

, Siemers

, Stern

, Yaffe

, Carrillo

, Thies

, Morrison-Bogorad

, Wagster

, Phelps

(2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.

Sevigny

, Chiao

, Bussiere

, Weinreb

, Williams

, Maier

, Dunstan

, Salloway

, Chen

, Ling

, O’Gorman

, Qian

, Arastu

, Li

, Chollate

, Brennan

, Quintero-Monzon

, Scannevin

, Arnold

, Engber

, Rhodes

, Ferrero

, Hang

, Mikulskis

, Grimm

, Hock

, Nitsch

, Sandrock

(2016) The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature537, 50–56.

Olsson

, Lautner

, Andreasson

, Ohrfelt

, Portelius

, Bjerke

, Holtta

, Rosen

, Olsson

, Strobel

, Wu

, Dakin

, Petzold

, Blennow

, Zetterberg

(2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: A systematic review and meta-analysis. Lancet Neurol15, 673–684.

Mattsson

, Zetterberg

, Blennow

(2010) Lessons from multicenter studies on CSF biomarkers for Alzheimer’s disease. Int J Alzheimers Dis2010, 610613.

10.

Blennow

, Vanmechelen

, Hampel

(2001) CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer’s disease. Mol Neurobiol24, 87–97.

11.

Jack

Jr , Bennett

, Blennow

, Carrillo

, Feldman

, Frisoni

, Hampel

, Jagust

, Johnson

, Knopman

, Petersen

, Scheltens

, Sperling

, Dubois

(2016) A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology87, 539–547.

12.

Albert

, DeKosky

, Dickson

, Dubois

, Feldman

, Fox

, Gamst

, Holtzman

, Jagust

, Petersen

, Snyder

, Carrillo

, Thies

, Phelps

(2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.

13.

McKhann

, Knopman

, Chertkow

, Hyman

, Jack

Jr , Kawas

, Klunk

, Koroshetz

, Manly

, Mayeux

, Mohs

, Morris

, Rossor

, Scheltens

, Carrillo

, Thies

, Weintraub

, Phelps

(2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.

14.

Dubois

, Feldman

, Jacova

, Hampel

, Molinuevo

, Blennow

, DeKosky

, Gauthier

, Selkoe

, Bateman

, Cappa

, Crutch

, Engelborghs

, Frisoni

, Fox

, Galasko

, Habert

, Jicha

, Nordberg

, Pasquier

, Rabinovici

, Robert

, Rowe

, Salloway

, Sarazin

, Epelbaum

, de Souza

, Vellas

, Visser

, Schneider

, Stern

, Scheltens

, Cummings

(2014) Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. Lancet Neurol13, 614–629.

15.

Hansson

, Zetterberg

, Buchhave

, Londos

, Blennow

, Minthon

(2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol5, 228–234.

16.

Mattsson

, Zetterberg

, Hansson

, Andreasen

, Parnetti

, Jonsson

, Herukka

, van der Flier

, Blankenstein

, Ewers

, Rich

, Kaiser

, Verbeek

, Tsolaki

, Mulugeta

, Rosen

, Aarsland

, Visser

, Schroder

, Marcusson

, de Leon

, Hampel

, Scheltens

, Pirttila

, Wallin

, Jonhagen

, Minthon

, Winblad

, Blennow

(2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA302, 385–393.

17.

Niemantsverdriet

, Valckx

, Bjerke

, Engelborghs

(2017) Alzheimer’s disease CSF biomarkers: Clinical indications and rational use. Acta Neurol Belg117, 591–602.

18.

Engelborghs

, Le Bastard

(2012) The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia. J Neurol Sci322, 197–199.

19.

Engelborghs

(2013) Clinical indications for analysis of Alzheimer’s disease CSF biomarkers. Rev Neurol (Paris)169, 709–714.

20.

Somers

, Struyfs

, Goossens

, Niemantsverdriet

, Luyckx

, De Roeck

, De Vil

, Cras

, Martin

, De Deyn

, Bjerke

, Engelborghs

(2016) A decade of cerebrospinal fluid biomarkers for Alzheimer’s disease in Belgium. J Alzheimers Dis54, 383–395.

21.

Lleo

, Cavedo

, Parnetti

, Vanderstichele

, Herukka

, Andreasen

, Ghidoni

, Lewczuk

, Jeromin

, Winblad

, Tsolaki

, Mroczko

, Visser

, Santana

, Svenningsson

, Blennow

, Aarsland

, Molinuevo

, Zetterberg

, Mollenhauer

(2015) Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nat Rev Neurol11, 41–55.

22.

Simonsen

, Herukka

, Andreasen

, Baldeiras

, Bjerke

, Blennow

, Engelborghs

, Frisoni

, Gabryelewicz

, Galluzzi

, Handels

, Kramberger

, Kulczynska

, Molinuevo

, Mroczko

, Nordberg

, Oliveira

, Otto

, Rinne

, Rot

, Saka

, Soininen

, Struyfs

, Suardi

, Visser

, Winblad

, Zetterberg

, Waldemar

(2017) Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimers Dement13, 274–284.

23.

Herukka

, Simonsen

, Andreasen

, Baldeiras

, Bjerke

, Blennow

, Engelborghs

, Frisoni

, Gabryelewicz

, Galluzzi

, Handels

, Kramberger

, Kulczynska

, Molinuevo

, Mroczko

, Nordberg

, Oliveira

, Otto

, Rinne

, Rot

, Saka

, Soininen

, Struyfs

, Suardi

, Visser

, Winblad

, Zetterberg

, Waldemar

(2017) Recommendations for cerebrospinal fluid Alzheimer’s disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimers Dement13, 285–295.

24.

Le Bastard

, Aerts

, Leurs

, Blomme

, De Deyn

, Engelborghs

(2009) No correlation between time-linked plasma and CSF Abeta levels. Neurochem Int55, 820–825.

25.

Le Bastard

, Leurs

, Blomme

, De Deyn

, Engelborghs

(2010) Plasma amyloid-beta forms in Alzheimer’s disease and non-Alzheimer’s disease patients. J Alzheimers Dis21, 291–301.

26.

De Vos

, Jacobs

, Struyfs

, Fransen

, Andersson

, Portelius

, Andreasson

, De Surgeloose

, Hernalsteen

, Sleegers

, Robberecht

, Van Broeckhoven

, Zetterberg

, Blennow

, Engelborghs

, Vanmechelen

(2015) C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer’s disease. Alzheimers Dement11, 1461–1469.

27.

Engelborghs

, Sleegers

, Cras

, Brouwers

, Serneels

, De Leenheir

, Martin

, Vanmechelen

, Van Broeckhoven

, De Deyn

(2007) No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer’s disease. Brain130, 2320–2326.

28.

Strozyk

, Blennow

, White

, Launer

(2003) CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology60, 652–656.

29.

Toledo

, Bjerke

, Da

, Landau

, Foster

, Jagust

, Jack

Jr , Weiner

, Davatzikos

, Shaw

, Trojanowski

, Alzheimer’s Disease Neuroimaging Initiative (2015) Nonlinear association between cerebrospinal fluid and Florbetapir F-18 beta-amyloid measures across the spectrum of Alzheimer disease. JAMA Neurol72, 571–581.

30.

Leuzy

, Chiotis

, Hasselbalch

, Rinne

, de Mendonca

, Otto

, Lleo

, Castelo-Branco

, Santana

, Johansson

, Anderl-Straub

, von Arnim

, Beer

, Blesa

, Fortea

, Herukka

, Portelius

, Pannee

, Zetterberg

, Blennow

, Nordberg

(2016) Pittsburgh compound B imaging and cerebrospinal fluid amyloid-beta in a multicentre European memory clinic study. Brain139, 2540–2553.

31.

Niemantsverdriet

, Ottoy

, Somers

, De Roeck

, Struyfs

, Soetewey

, Verhaeghe

, Van den Bossche

, Van Mossevelde

, Goeman

, De Deyn

, Marien

, Versijpt

, Sleegers

, Van Broeckhoven

, Wyffels

, Albert

, Ceyssens

, Stroobants

, Staelens

, Bjerke

, Engelborghs

(2017) The cerebrospinal fluid Abeta1-42/Abeta1-40 ratio improves concordance with amyloid-PET for diagnosing Alzheimer’s disease in a clinical setting. J Alzheimers Dis60, 561–576.

32.

Wallin

, Nordlund

, Jonsson

, Lind

, Edman

, Gothlin

, Stalhammar

, Eckerstrom

, Kern

, Borjesson-Hanson

, Carlsson

, Olsson

, Zetterberg

, Blennow

, Svensson

, Ohrfelt

, Bjerke

, Rolstad

, Eckerstrom

(2016) The Gothenburg MCI study: Design and distribution of Alzheimer’s disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up. J Cereb Blood Flow Metab36, 114–131.

33.

Buchhave

, Minthon

, Zetterberg

, Wallin

, Blennow

, Hansson

(2012) Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry69, 98–106.

34.

Koopman

, Le Bastard

, Martin

, Nagels

, De Deyn

, Engelborghs

(2009) Improved discrimination of autopsy-confirmed Alzheimer’s disease (AD) from non-AD dementias using CSF P-tau(181P). Neurochem Int55, 214–218.

35.

Struyfs

, Niemantsverdriet

, Goossens

, Fransen

, Martin

, De Deyn

, Engelborghs

(2015) Cerebrospinal fluid P-Tau181P: Biomarker for improved differential dementia diagnosis. Front Neurol6, 138.

36.

Bjerke

, Andreasson

, Rolstad

, Nordlund

, Lind

, Zetterberg

, Edman

, Blennow

, Wallin

(2009) Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement Geriatr Cogn Disord28, 348–356.

37.

Bjerke

, Zetterberg

, Edman

, Blennow

, Wallin

, Andreasson

(2011) Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer’s disease. J Alzheimers Dis27, 665–676.

38.

Slaets

, Le Bastard

, Theuns

, Sleegers

, Verstraeten

, De Leenheir

, Luyckx

, Martin

, Van Broeckhoven

, Engelborghs

(2013) Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis35, 137–146.

39.

Dorey

, Tholance

, Vighetto

, Perret-Liaudet

, Lachman

, Krolak-Salmon

, Wagner

, Struyfs

, De Deyn

, El-Moualij

, Zorzi

, Meyronet

, Streichenberger

, Engelborghs

, Kovacs

, Quadrio

(2015) Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol72, 267–275.

40.

Goossens

, Bjerke

, Struyfs

, Niemantsverdriet

, Somers

, Van den Bossche

, Van Mossevelde

, De Vil

, Sieben

, Martin

, Cras

, Goeman

, De Deyn

, Van Broeckhoven

, van der Zee

, Engelborghs

(2017) No added diagnostic value of non-phosphorylated tau fraction (p-taurel) in CSF as a biomarker for differential dementia diagnosis. Alzheimers Res Ther9, 49.

41.

Kanai

, Matsubara

, Isoe

, Urakami

, Nakashima

, Arai

, Sasaki

, Abe

, Iwatsubo

, Kosaka

, Watanabe

, Tomidokoro

, Shizuka

, Mizushima

, Nakamura

, Igeta

, Ikeda

, Amari

, Kawarabayashi

, Ishiguro

, Harigaya

, Wakabayashi

, Okamoto

, Hirai

, Shoji

(1998) Longitudinal study of cerebrospinal fluid levels of tau, A beta1-40, and A beta1-42(43) in Alzheimer’s disease: A study in Japan. Ann Neurol44, 17–26.

42.

Shoji

, Matsubara

, Kanai

, Watanabe

, Nakamura

, Tomidokoro

, Shizuka

, Wakabayashi

, Igeta

, Ikeda

, Mizushima

, Amari

, Ishiguro

, Kawarabayashi

, Harigaya

, Okamoto

, Hirai

(1998) Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer’s disease. J Neurol Sci158, 134–140.

43.

Palmqvist

, Mattsson

, Hansson

, Alzheimer’s Disease Neuroimaging Initiative (2016) Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. Brain139, 1226–1236.

44.

Janelidze

, Zetterberg

, Mattsson

, Palmqvist

, Vanderstichele

, Lindberg

, van Westen

, Stomrud

, Minthon

, Blennow

, Swedish BioFINDER study group, Hansson

(2016) CSF Abeta42/Abeta40 and Abeta42/Abeta38 ratios: Better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol3, 154–165.

45.

Lewczuk

, Matzen

, Blennow

, Parnetti

, Molinuevo

, Eusebi

, Kornhuber

, Morris

, Fagan

(2017) Cerebrospinal fluid Abeta42/40 corresponds better than Abeta42 to amyloid PET in Alzheimer’s disease. J Alzheimers Dis55, 813–822.

46.

Janelidze

, Pannee

, Mikulskis

, Chiao

, Zetterberg

, Blennow

, Hansson

(2017) Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol74, 1492–1501.

47.

Struyfs

, Van Broeck

, Timmers

, Fransen

, Sleegers

, Van Broeckhoven

, De Deyn

, Streffer

, Mercken

, Engelborghs

(2015) Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J Alzheimers Dis45, 813–822.

48.

Slaets

, Le Bastard

, Martin

, Sleegers

, Van Broeckhoven

, De Deyn

, Engelborghs

(2013) Cerebrospinal fluid Abeta1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels. J Alzheimers Dis36, 759–767.

49.

Dumurgier

, Schraen

, Gabelle

, Vercruysse

, Bombois

, Laplanche

, Peoc’h

, Sablonniere

, Kastanenka

, Delaby

, Pasquier

, Touchon

, Hugon

, Paquet

, Lehmann

(2015) Cerebrospinal fluid amyloid-beta 42/40 ratio in clinical setting of memory centers: A multicentric study. Alzheimers Res Ther7, 30.

50.

Hansson

, Zetterberg

, Buchhave

, Andreasson

, Londos

, Minthon

, Blennow

(2007) Prediction of Alzheimer’s disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord23, 316–320.

51.

Pijnenburg

, Verwey

, van der Flier

, Scheltens

, Teunissen

(2015) Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. Alzheimers Dement (Amst)1, 505–512.

52.

Lewczuk

, Lelental

, Lachmann

, Holzer

, Flach

, Brandner

, Engelborghs

, Teunissen

, Zetterberg

, Molinuevo

, Mroczko

, Blennow

, Popp

, Parnetti

, Chiasserini

, Perret-Liaudet

, Spitzer

, Maler

, Kornhuber

(2017) Non-phosphorylated tau as a potential biomarker of Alzheimer’s disease: Analytical and diagnostic characterization. J Alzheimers Dis55, 159–170.

53.

Brinkmalm

, Brinkmalm

, Bourgeois

, Persson

, Hansson

, Portelius

, Mercken

, Andreasson

, Parent

, Lipari

, Ohrfelt

, Bjerke

, Minthon

, Zetterberg

, Blennow

, Nutu

(2013) Soluble amyloid precursor protein alpha and beta in CSF in Alzheimer’s disease. Brain Res1513, 117–126.

54.

Somers

, Goossens

, Engelborghs

, Bjerke

(2017) Selecting Abeta isoforms for an Alzheimer’s disease cerebrospinal fluid biomarker panel. Biomark Med11, 169–178.

55.

Bjerke

, Jonsson

, Nordlund

, Eckerstrom

, Blennow

, Zetterberg

, Pantoni

, Inzitari

, Schmidt

, Wallin

(2014) Cerebrovascular biomarker profile is related to white matter disease and ventricular dilation in a LADIS substudy. Dement Geriatr Cogn Dis Extra4, 385–394.

56.

Le Bastard

, Van Buggenhout

, De Leenheir

, Martin

, De Deyn

, Engelborghs

(2007) LOW specificity limits the use of the cerebrospinal fluid Abeta1-42/P-TAU181P ratio to discriminate Alzheimer’s disease from vascular dementia. J Gerontol A Biol Sci Med Sci62, 923–924; author reply 924-925.

57.

Thorsell

, Bjerke

, Gobom

, Brunhage

, Vanmechelen

, Andreasen

, Hansson

, Minthon

, Zetterberg

, Blennow

(2010) Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res1362, 13–22.

58.

Wallin

, Ohrfelt

, Bjerke

(2012) Characteristic clinical presentation and CSF biomarker pattern in cerebral small vessel disease. J Neurol Sci322, 192–196.

59.

Rosenberg

, Bjerke

, Wallin

(2014) Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment. Stroke45, 1531–1538.

60.

Wallin

, Kapaki

, Boban

, Engelborghs

, Hermann

, Huisa

, Jonsson

, Kramberger

, Lossi

, Malojcic

, Mehrabian

, Merighi

, Mukaetova-Ladinska

, Paraskevas

, Popescu

, Ravid

, Traykov

, Tsivgoulis

, Weinstein

, Korczyn

, Bjerke

, Rosenberg

(2017) Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease – A consensus report. BMC Neurol17, 102.

61.

Jonsson

, Zetterberg

, Rolstad

, Edman

, Gouw

, Bjerke

, Lind

, Blennow

, Pantoni

, Inzitari

, Wallin

(2012) Low cerebrospinal fluid sulfatide predicts progression of white matter lesions: The LADIS study. Dement Geriatr Cogn Disord34, 61–67.

62.

Wallin

, Nordlund

, Jonsson

, Blennow

, Zetterberg

, Ohrfelt

, Stalhammar

, Eckerstrom

, Carlsson

, Olsson

, Gothlin

, Svensson

, Rolstad

, Eckerstrom

, Bjerke

(2016) Alzheimer’s disease–subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies. J Cereb Blood Flow Metab36, 95–113.

63.

Hjalmarsson

, Bjerke

, Andersson

, Blennow

, Zetterberg

, Aberg

, Olsson

, Eckerstrom

, Bokemark

, Wallin

(2014) Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke. J Cent Nerv Syst Dis6, 51–58.

64.

Zetterberg

, Skillback

, Mattsson

, Trojanowski

, Portelius

, Shaw

, Weiner

, Blennow

, Alzheimer’s Disease Neuroimaging Initiative (2016) Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol73, 60–67.

65.

Sieben

, Van Langenhove

, Engelborghs

, Martin

, Boon

, Cras

, De Deyn

, Santens

, Van Broeckhoven

, Cruts

(2012) The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol124, 353–372.

66.

Goossens

, Vanmechelen

, Trojanowski

, Lee

, Van Broeckhoven

, van der Zee

, Engelborghs

(2015) TDP-43 as a possible biomarker for frontotemporal lobar degeneration: A systematic review of existing antibodies. Acta Neuropathol Commun3, 15.

67.

Sleegers

, Brouwers

, Van Damme

, Engelborghs

, Gijselinck

, van der Zee

, Peeters

, Mattheijssens

, Cruts

, Vandenberghe

, De Deyn

, Robberecht

, Van Broeckhoven

(2009) Serum biomarker for progranulin-associated frontotemporal lobar degeneration. Ann Neurol65, 603–609.

68.

Ghidoni

, Benussi

, Glionna

, Franzoni

, Binetti

(2008) Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. Neurology71, 1235–1239.

69.

Simonsen

, Kuiperij

, El-Agnaf

, Engelborghs

, Herukka

, Parnetti

, Rektorova

, Vanmechelen

, Kapaki

, Verbeek

, Mollenhauer

(2016) The utility of alpha-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. Biomark Med10, 19–34.

70.

Kruse

, Persson

, Alcolea

, Bahl

, Baldeiras

, Capello

, Chiasserini

, Bocchio Chiavetto

, Emersic

, Engelborghs

, Eren

, Fladby

, Frisoni

, Garcia-Ayllon

, Genc

, Gkatzima

, Heegaard

, Janeiro

, Kovacech

, Kuiperij

, Leitao

, Lleo

, Martins

, Matos

, Mollergard

, Nobili

, Ohrfelt

, Parnetti

, de Oliveira

, Rot

, Saez-Valero

, Struyfs

, Tanassi

, Taylor

, Tsolaki

, Vanmechelen

, Verbeek

, Zilka

, Blennow

, Zetterberg

, Mollenhauer

(2015) Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging36, 2587–2596.

71.

Slaets

, Vanmechelen

, Le Bastard

, Decraemer

, Vandijck

, Martin

, De Deyn

, Engelborghs

(2014) Increased CSF alpha-synuclein levels in Alzheimer’s disease: Correlation with tau levels. Alzheimers Dement10, S290–S298.

72.

Zerr

, Bodemer

, Gefeller

, Otto

, Poser

, Wiltfang

, Windl

, Kretzschmar

, Weber

(1998) Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol43, 32–40.

73.

Van Everbroeck

, Quoilin

, Boons

, Martin

, Cras

(2003) A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry74, 1210–1214.

74.

Bjerke

, Portelius

, Minthon

, Wallin

, Anckarsater

, Andreasen

, Zetterberg

, Andreasson

, Blennow

(2010) Confounding factors influencing amyloid Beta concentration in cerebrospinal fluid. Int J Alzheimers Dis2010, 986310.

75.

Le Bastard

, De Deyn

, Engelborghs

(2015) Importance and impact of preanalytical variables on Alzheimer disease biomarker concentrations in cerebrospinal fluid. Clin Chem61, 734–743.

76.

Willemse

, van Uffelen

, Brix

, Engelborghs

, Vanderstichele

, Teunissen

(2017) How to handle adsorption of cerebrospinal fluid amyloid-beta (1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Abeta42/Abeta40 ratio. Alzheimers Dement13, 885–892.

77.

Lewczuk

, Beck

, Esselmann

, Bruckmoser

, Zimmermann

, Fiszer

, Bibl

, Maler

, Kornhuber

, Wiltfang

(2006) Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clin Chem52, 332–334.

78.

Niemantsverdriet

, Goossens

, Struyfs

, Martin

, Goeman

, De Deyn

, Vanderstichele

, Engelborghs

(2016) Diagnostic impact of cerebrospinal fluid biomarker (pre-)analytical variability in Alzheimer’s disease. J Alzheimers Dis51, 97–106.

79.

Bjerke

, Andreasson

, Kuhlmann

, Portelius

, Pannee

, Lewczuk

, Umek

, Vanmechelen

, Vanderstichele

, Stoops

, Lewis

, Vandijck

, Kostanjevecki

, Jeromin

, Salamone

, Schmidt

, Matzen

, Madin

, Eichenlaub

, Bittner

, Shaw

, Zegers

, Zetterberg

, Blennow

(2016) Assessing the commutability of reference material formats for the harmonization of amyloid-beta measurements. Clin Chem Lab Med54, 1177–1191.

80.

Mattsson

, Zegers

, Andreasson

, Bjerke

, Blankenstein

, Bowser

, Carrillo

, Gobom

, Heath

, Jenkins

, Jeromin

, Kaplow

, Kidd

, Laterza

, Lockhart

, Lunn

, Martone

, Mills

, Pannee

, Ratcliffe

, Shaw

, Simon

, Soares

, Teunissen

, Verbeek

, Umek

, Vanderstichele

, Zetterberg

, Blennow

, Portelius

(2012) Reference measurement procedures for Alzheimer’s disease cerebrospinal fluid biomarkers: Definitions and approaches with focus on amyloid beta42. Biomark Med6, 409–417.

81.

Kuhlmann

, Andreasson

, Pannee

, Bjerke

, Portelius

, Leinenbach

, Bittner

, Korecka

, Jenkins

, Vanderstichele

, Stoops

, Lewczuk

, Shaw

, Zegers

, Schimmel

, Zetterberg

, Blennow

, IFCC Working Group on Standardization of CSF proteins (WG-CSF) (2017) CSF Abeta1-42 – an excellent but complicated Alzheimer’s biomarker – a route to standardisation. Clin Chim Acta467, 27–33.

82.

Mattsson

, Andreasson

, Persson

, Arai

, Batish

, Bernardini

, Bocchio-Chiavetto

, Blankenstein

, Carrillo

, Chalbot

, Coart

, Chiasserini

, Cutler

, Dahlfors

, Duller

, Fagan

, Forlenza

, Frisoni

, Galasko

, Galimberti

, Hampel

, Handberg

, Heneka

, Herskovits

, Herukka

, Holtzman

, Humpel

, Hyman

, Iqbal

, Jucker

, Kaeser

, Kaiser

, Kapaki

, Kidd

, Klivenyi

, Knudsen

, Kummer

, Lui

, Llado

, Lewczuk

, Li

, Martins

, Masters

, McAuliffe

, Mercken

, Moghekar

, Molinuevo

, Montine

, Nowatzke

, O’Brien

, Otto

, Paraskevas

, Parnetti

, Petersen

, Prvulovic

, de Reus

, Rissman

, Scarpini

, Stefani

, Soininen

, Schroder

, Shaw

, Skinningsrud

, Skrogstad

, Spreer

, Talib

, Teunissen

, Trojanowski

, Tumani

, Umek

, Van Broeck

, Vanderstichele

, Vecsei

, Verbeek

, Windisch

, Zhang

, Zetterberg

, Blennow

(2011) The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement7, 386-395 e386.

83.

Molinuevo

, Blennow

, Dubois

, Engelborghs

, Lewczuk

, Perret-Liaudet

, Teunissen

, Parnetti

(2014) The clinical use of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement10, 808–817.

84.

Vanderstichele

, Bibl

, Engelborghs

, Le Bastard

, Lewczuk

, Molinuevo

, Parnetti

, Perret-Liaudet

, Shaw

, Teunissen

, Wouters

, Blennow

(2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer’s disease diagnosis: A consensus paper from the Alzheimer’s Biomarkers Standardization Initiative. Alzheimers Dement8, 65–73.

Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis

Abstract

Keywords

INTRODUCTION

BIOMARKER ASSOCIATION WITH NEUROPATHOLOGY AND DETECTION OF DEFINITE AND CLINICAL AD

THE ADDED VALUE OF CSF BIOMARKERS FOR EARLY AND DIFFERENTIAL AD DIAGNOSIS

NEW AD AND NON-AD RELATED BIOMARKERS FOR IMPROVED DIFFERENTIAL DIAGNOSIS

IMPROVEMENT AND HARMONIZATION OF AD CSF BIOMARKER MEASUREMENTS

CONCLUDING REMARKS

Footnotes

ACKNOWLEDGMENTS

References